[HTML][HTML] Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma

P Kozakiewicz… - Oncology …, 2018 - spandidos-publications.com
P Kozakiewicz, L Grzybowska‑Szatkowska
Oncology letters, 2018spandidos-publications.com
Despite the development of standard therapies, including surgery, radiotherapy and
chemotherapy, survival rates for head and neck squamous cell carcinoma (HNSCC) have
not changed significantly over the past three decades. Complete recovery is achieved in<
50% of patients. The treatment of advanced HNSCC frequently requires multimodality
therapy and involves significant toxicity. The promising, novel treatment option for patients
with HNSCC is molecular‑targeted therapies. The best known targeted therapies include …
Abstract
Despite the development of standard therapies, including surgery, radiotherapy and chemotherapy, survival rates for head and neck squamous cell carcinoma (HNSCC) have not changed significantly over the past three decades. Complete recovery is achieved in< 50% of patients. The treatment of advanced HNSCC frequently requires multimodality therapy and involves significant toxicity. The promising, novel treatment option for patients with HNSCC is molecular‑targeted therapies. The best known targeted therapies include: Epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab, panitumumab, zalutumumab and nimotuzumab), EGFR tyrosine kinase inhibitors (gefitinib, erlotinib, lapatinib, afatinib and dacomitinib), vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) or vascular endothelial growth factor receptor (VEGFR) inhibitors (sorafenib, sunitinib and vandetanib) and inhibitors of phosphatidylinositol 3-kinase/serine/threonine-specific protein kinase/mammalian target of rapamycin. There are also various inhibitors of other pathways and targets, which are promising and require evaluation in further studies.
Spandidos Publications